Develops inhaled drugs for migraine and respiratory diseases.
Dec 2024Revenue $7.81M/yrExpenses $17.6M/yr
Expected break-even Oct 2027Cash runway ≈ 7 months from Jun 2026
Figures by year
When will Pulmatrix be profitable?
Its revenue and expense trends are projected to cross in Oct 2027. In the 12 months to Dec 2024, revenue was $7.81M and expenses $17.6M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $7.81M | $17.6M | −$9.76M |
| Dec 2023 | $7.30M | $22.0M | −$14.7M |
| Dec 2022 | $6.07M | $25.0M | −$18.9M |
| Dec 2021 | $5.17M | $25.3M | −$20.2M |
| Dec 2020 | $12.6M | $22.5M | −$9.86M |
| Dec 2019 | $7.91M | $28.6M | −$20.7M |
| Dec 2018 | $153K | $20.6M | −$20.4M |
| Dec 2017 | $335K | $17.8M | −$17.5M |
| Dec 2016 | $835K | $25.7M | −$24.9M |
| Dec 2015 | $1.20M | $24.2M | −$23.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.